Industrial, Manufacturing & Heavy Industry Market News

Overactive bladder treatment market size hit $4.19 billion by 2022 according to new research report

Overactive bladder treatment market size hit $4.19 billion by 2022 according to new research report

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders To profile the key players in the global market and comprehensively analyze their market shares and core competencies To track and analyze competitive developments of key players in the global market

- Agency -.

“Global overactive bladder treatment market is projected to grow at a CAGR of 2.9%.”

The global overactive bladder treatment market is estimated to grow at a CAGR of 2.9% from 2017 to 2022, to reach USD 4.19 billion by 2022. 

www.rnrmarketresearch.com/contacts…ple?rname=1151258 

The key factors driving the growth of this market include the rising prevalence of overactive bladder (OAB) coupled with the growing geriatric population and rising neurological disorders, namely, Parkinson’s Disease (PD), stroke, and multiple sclerosis (MS). However, the undesired systemic effects of current OAB treatments may hinder the growth of the market to a certain extent during the forecast period.

“The neurostimulation and BOTOX treatment segments are expected to grow at the highest CAGR.”

On the basis of pharmacotherapy, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, and neurostimulation. The neurostimulation and BOTOX treatment segments are expected to witness the highest growth during the forecast period.

- Agency -.

The growth of these segments is mainly due to the higher efficacy and longevity of the treatment effects as compared to anticholinergics.

Report: www.rnrmarketresearch.com/contacts/?rname=1151258

*Top 15 Companies Analyzed for This Studies are - Some of the major market players in the overactive bladder treatment market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V.

(U.S.), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co.,Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc.

(Canada), and Cogentix Medical, Inc. (U.S.).

Target Audience:

  • Drug manufacturers, vendors, and distributors
  • Academic and government research institutes
  • Contract manufacturing organizations (CMOs) and contract research organizations (CROs)
  • Venture capitalists and investors

 Key point from table of content 

5 Global Overactive Bladder Treatment Market, By Pharmacotherapy
5.1 Introduction
5.2 Anticholinergics
5.2.1 Solifenacin
5.2.2 Oxybutynin 

6 Global Overactive Bladder Treatment Market, By Disease
6.1 Introduction
6.2 Idiopathic Overactive Bladder 
6.3 Neurogenic Overactive Bladder 

8 Marketed Products
8.1 Marketed Products for Overactive Bladder Syndrome in the U.S. 
8.2 Marketed Products for Overactive Bladder Syndrome in EU-5

9 Pipeline Products
9.1 Pipeline Products for Overactive Bladder Syndrome in the U.S. 
9.2 Pipeline Products for Overactive Bladder Syndrome in EU-5 

Browse Here for full Report with TOC: www.rnrmarketresearch.com/overacti…arket-report.html

News From

RnR Market Research - Market Research and Competitive Analysis ReportsRnR Market Research
Category: Market Research Publishers and RetailersCompany profile: RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.